This article is part of the supplement: Proceedings of the 8th Global Arthritis Research Network (GARN) Meeting and 1st Bio-Rheumatology International Congress (BRIC)
GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded end point (PROBE) trial
Arthritis Research & Therapy 2012, 14(Suppl 1):P63 doi:10.1186/ar3664
Accesses
- Last 30 days: 30 accesses
- Last 365 days: 540 accesses
- All time: 667 accesses

